索引于
  • 学术期刊数据库
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Extrapyramidal Symptoms in Patients Treated with Antipsychotic Drugs

Werner FM and Coveñas R

Extrapyramidal symptoms are adverse effects of second-generation antipsychotic drugs which are generally used to treat schizophrenia and schizoaffective disorder. These adverse effects are due to the D2 receptor blockade. Neurotransmitter and neuropeptide alterations in the mesolimbic system and in the extrapyramidal system and the derived neural networks are described. M4 antagonists, GABAA agonists or NMDA antagonists can be used to treat the extrapyramidal symptoms because they improve the dopaminergic-cholinergic neurotransmitter imbalance in this neural system. Recently developed antipsychotic drugs such as aripiprazole and cariprazine cause less often and, to a lesser extent, extrapyramidal symptoms because they exert a partial agonism at the D2 receptor.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证